Advancements in Pulmonary Fibrosis Treatment: A Company's Efforts in September
September is Pulmonary Fibrosis Awareness Month, shedding light on the chronic and fatal lung disease known as Idiopathic Pulmonary Fibrosis (IPF). GRI Bio, a clinical-stage biopharmaceutical company, is dedicated to developing therapies that interrupt disease progression and restore the immune system's balance. Their lead drug, GRI-0621, inhibits the activity of iNKT cells involved in the inflammatory cascade leading to fibrotic disorders like IPF. Preclinical studies have shown promising results, and the drug has significant IP protection until 2038 or beyond. GRI Bio has collaborated with the Respiratory Translational Research Collaboration to further de-risk the drug's development program. The company is approaching IND filings and clearance for a phase 2a biomarker study.
